Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject \>=2 years of age.~* Allogeneic HSCT for hematologic disorder.~* Allogeneic HSCT with full myeloablative conditioning or reduced intensity conditioning.~* Allogeneic HSCT approximately 3 to 6 months (91 days to 203 days) before enrollment.~* Stable engraftment (absolute neutrophil count (ANC) \>1000/µL; platelet count \>50,000/µL).~* Complete hematologic remission of underlying disease with very good partial remission (VGPR) acceptable in the case of lymphoma and myeloma.~* Subject or parent/legal guardian expected to be available for the entire study and can be contacted by telephone.~* Subject or parent/legal guardian must be able to complete an electronic diary (e-diary) and complete all relevant study procedures during study participation.~* Hematological recovery as defined by ANC \>1000/µL; platelet count \>50,000/µL.~* All female and male subjects who are biologically capable of having children must agree to abstinence or commit to the use of a reliable method of birth control from signing of the ICF until for 3 months after the last vaccination.~* Negative urine pregnancy test for all female subjects of child bearing potential.~Exclusion Criteria:~* Autologous HSCT.~* Receipt of donor lymphocyte infusions during the 28 days preceding enrollment.~* Uncontrolled GVHD that in the opinion of the investigator would prevent the subject from participating in the study.~* Lansky/Karnofsky Score \<=60%.~* Receipt of plasma products or immunoglobulins during the 60 days preceding enrollment.~* Receipt of rituximab since HSCT.~* Receipt of chemotherapy for relapse of underlying malignant disease since HSCT.~* Human immunodeficiency virus (HIV) infection.~* Lymphoproliferative disorder since HSCT.~* Chronic illnesses with cardiac, pulmonary, renal, or liver failure that in the opinion of the investigator would prevent the subject participating in the study.~* Vaccination with any licensed or experimental pneumococcal vaccine since HSCT.~* Previous anaphylactic reaction to any vaccine or vaccine-related component.~* Bleeding diathesis or condition associated with prolonged bleeding time that would in the opinion of the investigator contraindicate intramuscular injection.~* Participation in another study with ongoing use of an unlicensed investigational product from 28 days before study enrollment until the end of the study.~* Participation in another study with ongoing use of a licensed investigational product that in the opinion of the investigator would interfere with the evaluation of the study objectives.~* Permanent residence in a nursing home or other residential care facility.~* Pregnant or breastfeeding female subject.~* Subject who is a direct relative (child, grandchild, parent, or grandparent) of study personnel, or is a member of the study personnel.~* Receipt of advanced therapy medicinal products (ATMP) including gene therapy products, somatic cell therapy products, and tissue engineered products at any time before enrollment.~* If information is available, - previous allergic or anaphylactic reaction to any vaccine or vaccine-related component in a stem cell donor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete